Pfizer und BioNTech reichen Antrag für Notfallzulassung eines angepassten bivalenten COVID-19-Impfstoffs für Omikron-Varianten BA.4/BA.5 bei der FDA ein
August 22, 2022 10:30 ET
|
BioNTech SE
Die Daten stützen Antrag auf Notfallzulassung einer 30-µg-Auffrischungsdosis eines an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoffs für Personen ab 12 JahrenDie Unternehmen haben die...
Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
August 22, 2022 10:30 ET
|
BioNTech SE
Data support request for Emergency Use Authorization of a 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and olderCompanies have rapidly...
Wärtsilä in U.S. customer collaboration to test hydrogen blended fuel as a step towards decarbonised power plant operations
May 31, 2022 13:22 ET
|
Wartsila
HELSINKI, Finland, May 31, 2022 (GLOBE NEWSWIRE) -- The technology group Wärtsilä, in collaboration with WEC Energy Group, (WEC), the Electric Power Research Institute (EPRI) and Burns &...
Crosschq Acquires TalentWall To Expand Data and Analytics Capabilities for Global Talent Leaders
May 17, 2022 07:00 ET
|
Crosschq
DANVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Crosschq, pioneers of the Talent Intelligence Cloud™ that is powering a revolution in data-driven hiring and people analytics, announced today it...
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
March 15, 2022 18:00 ET
|
BioNTech SE
Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who...
Innospec Expands Customer Technical Support With New Fuels Technology Center
March 09, 2022 16:45 ET
|
Innospec Inc.
ENGLEWOOD, Colo., March 09, 2022 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ: IOSP) today announced the opening of its new Technology Center in Ellesmere Port, UK. The facility reinforces the...
Truveta announces new COVID-19 insights and unveils Truveta platform for the first time at #ViVE2022
March 08, 2022 12:04 ET
|
Truveta
Bellevue, WASH, March 08, 2022 (GLOBE NEWSWIRE) -- Truveta, the health system-led company with a vision of saving lives with data, unveiled the Truveta platform in its first public demonstration at...
Pfizer und BioNTech beginnen klinische Studie zu Omikron-basiertem COVID-19-Impfstoff bei Erwachsenen im Alter von 18-55 Jahren
January 25, 2022 06:45 ET
|
BioNTech SE
Die ersten Teilnehmer erhielten im Rahmen der klinischen Studie den Omikron-basierten Impfstoffkandidaten als Impfserie mit zwei Dosen oder als Auffrischungsimpfung NEW YORK und MAINZ, Deutschland,...
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
January 25, 2022 06:45 ET
|
BioNTech SE
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc....
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
December 09, 2021 12:15 ET
|
BioNTech SE
First emergency use authorization in the United States for a COVID-19 vaccine booster in individuals 16 years and older NEW YORK and MAINZ, Germany, December 9, 2021 — Pfizer Inc. (NYSE: PFE) and...